Drink plenty of fluids and eat whole foods to prevent nausea
Influence of gastric emptying on the control of postprandial glycemia: physiology and therapeutic implications
For users already experiencing fatigue on tirzepatide , the added B3 may provide noticeable energy benefits
Outcomes The outcomes are (1) changes in HbA1c and ALT levels 6 months after the prescription of either SGLT2i or DPP4i, (2) changes in hepatic fibrosis indexes including platelet, FIB-4 index, Forns index, AST/ALT ratio, and Diabetes Mellitus-hepatocellular carcinoma (DM-HCC) risk score from baseline over 12 months, (3) the incidence of newly diagnosed liver-related events (liver cancer (ICD-10: C22), cirrhosis (ICD-10: K74.6, K76.7, R18), liver failure (ICD-10: K72), esophageal varices (ICD-10: I85, I86.4)), extrahepatic cancer (ICD-10: C00-C21, C23-C96), and cardiovascular events (myocardial infarction (ICD-10: I21), angina (ICD-10: I20), atrial fibrillation (ICD-10: I48), stroke (ICD-10: I60-I64), heart failure (ICD-10: I50), cardiac arrest (ICD-10: I46)) during 12 months (Supplementary Table 1)